264 related articles for article (PubMed ID: 12115946)
1. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.
De Feo LG; Schottlender J; Martelli NA; Molfino NA
Muscle Nerve; 2002 Jul; 26(1):31-6. PubMed ID: 12115946
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
[TBL] [Abstract][Full Text] [Related]
3. An atypical course of myasthenia gravis.
Labana SS; Qureshi S; Nandakumar T; Cervellione KL; Venkatraman GK; Thakore H; Gintautas J
Proc West Pharmacol Soc; 2007; 50():140-2. PubMed ID: 18605252
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis.
Nagappa M; Netravathi M; Taly AB; Sinha S; Bindu PS; Mahadevan A
J Clin Neurosci; 2014 Nov; 21(11):1909-14. PubMed ID: 25043165
[TBL] [Abstract][Full Text] [Related]
5. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Kupersmith MJ; Ying G
Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ocular symptoms in myasthenia gravis.
Bhanushali MJ; Wuu J; Benatar M
Neurology; 2008 Oct; 71(17):1335-41. PubMed ID: 18936425
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
Ribi C; Cohen P; Pagnoux C; Mahr A; Arène JP; Lauque D; Puéchal X; Letellier P; Delaval P; Cordier JF; Guillevin L;
Arthritis Rheum; 2008 Feb; 58(2):586-94. PubMed ID: 18240234
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
10. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
11. The effect of use of pyridostigmine and requirement of vecuronium in patients with myasthenia gravis.
Tripathi M; Kaushik S; Dubey P
J Postgrad Med; 2003; 49(4):311-4; discussion 314-5. PubMed ID: 14699228
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.
Tindall RS; Rollins JA; Phillips JT; Greenlee RG; Wells L; Belendiuk G
N Engl J Med; 1987 Mar; 316(12):719-24. PubMed ID: 3547126
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of pediatric ocular myasthenia gravis.
Ortiz S; Borchert M
Ophthalmology; 2008 Jul; 115(7):1245-1248.e1. PubMed ID: 18155768
[TBL] [Abstract][Full Text] [Related]
14. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
Li X; Li H; Chen J; He Q; Lv R; Lin W; Li Q; He X; Qu L; Suya W
Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
[TBL] [Abstract][Full Text] [Related]
16. [Dysphagia as the sole manifestation of myasthenia gravis].
Romo González RJ; Chaves E; Copello H
Acta Gastroenterol Latinoam; 2010 Jun; 40(2):156-8. PubMed ID: 20645565
[TBL] [Abstract][Full Text] [Related]
17. An unusual presentation of myasthenia gravis.
Chijoke A; Ogunmodele JA
West Afr J Med; 2009; 28(6):391-3. PubMed ID: 20486100
[TBL] [Abstract][Full Text] [Related]
18. Childhood myasthenia gravis.
Berkovitz S; Belkin M; Tenenbaum A
J Pediatr Ophthalmol; 1977; 14(5):269-73. PubMed ID: 925839
[TBL] [Abstract][Full Text] [Related]
19. Childhood myasthenia gravis: clinical features and outcomes.
Sri-udomkajorn S; Panichai P; Liumsuwan S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
[TBL] [Abstract][Full Text] [Related]
20. A cause of reversible dysphagia: an unusual presentation of myasthenia gravis.
Brostoff JM; Dahdaleh D; Birns J
Eur J Intern Med; 2008 Jan; 19(1):70. PubMed ID: 18206608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
